Bayesian adaptive methods for clinical trials / Scott M. Berry ... [et al.].
Material type: TextSeries: Chapman & Hall/CRC biostatistics series ; 38.Publication details: Boca Raton : Chapman & Hall/CRC, 2011.Description: 323 p. ; [ca. 23-29] cmISBN:- 9781439825488
- R853.C55 B385 2011
- Also available as an electronic resource.
Item type | Current library | Call number | Status | Date due | Barcode | Item holds | |
---|---|---|---|---|---|---|---|
Books | ISI Library, Kolkata NBHM Collection | 000SB:615.50724 B534 (Browse shelf(Opens below)) | Available | 131948 |
Browsing ISI Library, Kolkata shelves, Shelving location: NBHM Collection Close shelf browser (Hides shelf browser)
No cover image available | ||||||||
000SB:614.42 L425 Bayesian disease mapping : | 000SB:615.1 Se478 Statistical issues in drug development | 000SB:615.19 J94 Introduction to statistics in early phase trials | 000SB:615.50724 B534 Bayesian adaptive methods for clinical trials / | 000SB:615.580724 H844 Dynamic prediction in clinical survival analysis / | 000SB:615.9 K92 Statistics in toxicology | 000SB:615 C771 Introduction to statistical methods for clinical trials |
Includes bibliographical references and indexes.
(Publisher-supplied data) Statistical approaches for clinical trials -- Basics of Bayesian inference -- Phase I studies -- Phase II studies -- Phase III studies -- Special topics.
"As has been well-discussed, the explosion of interest in Bayesian methods over the last 10 to 20 years has been the result of the convergence of modern computing power and e�cient Markov chain Monte Carlo (MCMC) algo- rithms for sampling from and summarizing posterior distributions. Prac- titioners trained in traditional, frequentist statistical methods appear to have been drawn to Bayesian approaches for three reasons. One is that Bayesian approaches implemented with the majority of their informative content coming from the current data, and not any external prior informa- tion, typically have good frequentist properties (e.g., low mean squared er- ror in repeated use). Second, these methods as now readily implemented in WinBUGS and other MCMC-driven software packages now oʼer the simplest approach to hierarchical (random eʼects) modeling, as routinely needed in longitudinal, frailty, spatial, time series, and a wide variety of other settings featuring interdependent data. Third, practitioners are attracted by the greater �exibility and adaptivity of the Bayesian approach, which permits stopping for e�cacy, toxicity, and futility, as well as facilitates a straightforward solution to a great many other specialized problems such as dose-nding, adaptive randomization, equivalence testing, and others we shall describe. This book presents the Bayesian adaptive approach to the design and analysis of clinical trials"--Provided by publisher.
Also available as an electronic resource.
There are no comments on this title.